Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%).

Clindamycin Phosphate Gel USP, 1% is used to treat acne. It helps to decrease the number of acne lesions. Clindamycin is an antibiotic which works by stopping the growth of bacteria. The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).

Clindamycin Phosphate Gel USP, 1% had annual sales of USD 37 mn in the United States (IQVIA MAT July 2023).

The group now has 381 approvals and has so far filed over 444* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 624.50 as compared to the previous close of Rs. 643.45. The total number of shares traded during the day was 48222 in over 2605 trades.

The stock hit an intraday high of Rs. 645.00 and intraday low of 623.40. The net turnover during the day was Rs. 30471162.00.

(*as of 30th June 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA ClindamycinPhosphateGel